FMP
XETRA
2.94 EUR
0 (0%)
Dr. Niels C. Riedemann M.D., Ph.D.
Healthcare
Biotechnology
https://www.inflarx.de
XETRA
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune dis...
N/A
N/A
N/A
Winzerlaer Str. 2
49 3641 508 180
DE
62
Dec 2, 2019
-
XETRA
Biotechnology
Healthcare
-
-
DE
2.94
1.3
5.14k
129.91M
-
0.93-5.09
0
-
-
-
-
-2.43
-
https://www.inflarx.de
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.